PPCB

MELBOURNE, Australia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced new preclinical data supporting the potential of its lead asset, PRP (a proprietary fixed-ratio 1:6 intravenous formulation of trypsinogen and chymotrypsinogen), to address chemotherapy resistance in pancreatic cancer. In collaborative research led by Dr. Maria Belén Toledo at the Universities of Jaén and Granada, PRP was shown to remodel the resistant cellular state in pancreatic cancer models with acquired chemotherapy r

MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, please note that in the third paragraph of the release, the "Reverse Stock Split date" should be "October 26, 2026," not "October 19, 2026," as previously stated. This correction is being issued to reflect the correct Reverse Stock Split date. The corrected release follows:  Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that its Board of Directors, approved a 1-for-10 reverse stock split of the Company’s issue

MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that its Board of Directors, approved a 1-for-10 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share ("Reverse Stock Split"). The Reverse Stock Split is anticipated to be effective as of the open of the market October 26, 2026. As a result of the Reverse Stock Split, every 10 pre-split shares of Company common stock outstanding will automatically combine into one n

DEF 14C - Propanc Biopharma, Inc. (0001517681) (Filer)

MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, has identified pancreatic proenzyme formulation, PRP, as a potential strategy for addressing chemotherapy resistance in pancreatic cancer. Chemotherapy-resistant tumor cells can acquire adaptive cellular states that allow them to survive treatment and maintain aggressive characteristics

MELBOURNE, Australia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced the publication of a peer-reviewed pilot study in Scientific Reports (Nature Publishing Group) titled "A formulation of pancreatic pro-enzymes provides potent anti-tumor efficacy: a pilot study focused on pancreatic and ovarian cancer." The study evaluates PRP, the Company’s proprietary fixed-ratio combination of the pancreatic proenzymes Trypsinogen and Chymotrypsinogen A (1:6). Across 24 human cancer cell lines, the 1:6

PRE 14C - Propanc Biopharma, Inc. (0001517681) (Filer)

MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today highlighted new preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and compared that profile with a clinical standard recently established by Revolution Medicines, Inc. On August 26, 2026, the U.S. Food and Drug Administration approved daraxonrasib (RASONQUE), Revolution Medicines’ oral RAS(ON) multi-selective inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at lea

S-1 - Propanc Biopharma, Inc. (0001517681) (Filer)

MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported year-end financial results as of June 30, 2026 (Year end June 30). CORPORATE HIGHLIGHTS To commence a world-first Phase 1b FIH study of PRP in Q1, 2027 The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across Australia. The two-part design, dose escalati

10-K - Propanc Biopharma, Inc. (0001517681) (Filer)

New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset MELBOURNE, Australia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of lead candidate PRP against recently reported clinical datasets from Erasca, Inc.’s pan-RAS molecular glue ERAS-0015 in pancreatic ductal adenocarcinoma (PDAC). The analysis follows FDA approval of R

MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of its lead candidate PRP against recently reported clinical datasets from leading RAS-targeted programs, including Revolution Medicines’ daraxonrasib (RASONQUE™; RMC-6236) and Erasca’s pan-RAS molecular glue ERAS-0015. The analysis is intended to clarify two distinct layers of tumor biology. RAS inhibitors block oncogenic RAS signaling and have produced practice-changing clinical results in RAS-mutan

MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced plans to commence a world-first Phase 1b first-in-human (FIH) study of PRP in February 2027. The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across Australia. The two-part design, dose escalation (Part A) followed by dose expansion (Part B), is intended to evaluate the safety, tolerability, pharmac

MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, three-times-weekly intravenous PRP achieved: Greater than 90%, mean, tumor growth inhibition versus vehicle controls (p < 0.001).Marked reduction in metastatic burden in the liver and peritoneum.Significant remodeling of t

MELBOURNE, Australia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human (FIH), Phase 1b clinical study of PRP in up to 40 advanced cancer patients suffering from solid tumors. Preparatory activities for the multi-trial center investigation will be led by Avance Clinical Pty Ltd and will consist of a detailed review of the Company’s Investigator’s Brochure (IB), preparatio

MELBOURNE, Australia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today provided a scientific comparison of its lead candidate PRP with the RAS-targeted approaches of Revolution Medicines, Inc. and Erasca, Inc. The Company articulates why PRP’s unique mechanism—promoting cancer cell differentiation, reversing epithelial-mesenchymal transition (EMT), and targeting cancer stem cells via pancreatic proenzymes—positions it as a potential long-term therapy of choice, particularly for aggressive, treatment-re

MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and treatment-resistant solid tumors. In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, 3 times weekly intravenous PRP achieved: Greater than 90% mean tumor growth inhibition versus vehicle controls (p < 0.001)Marked reduction in metastatic burden in

MELBOURNE, Australia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it is completing the first tranche of $500,000 within the first 30 days since commencing its share repurchase program. "We will continue to honor our share repurchase program as we believe the Company is significantly undervalued as we progress to a world first, Phase 1b, First-In-Human study in 40 – 45 advanced cancer patients suffering from solid tumors, to be rolled out nationally in trial centers across Australia. Fur

EFFECT - Propanc Biopharma, Inc. (0001517681) (Filer)

S-1 - Propanc Biopharma, Inc. (0001517681) (Filer)

8-K - Propanc Biopharma, Inc. (0001517681) (Filer)

MELBOURNE, Australia, July 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has initiated a share repurchase program authorizing the Company to repurchase a first tranche of up to $500,000 over the next 30-day period. "We are pleased to commence this share repurchase program with this initial commitment, as we strongly believe the Company is entering a transformative stage of development as it advances its lead asset, PRP, into the clinic," said Mr. James Nathanielsz, Propanc’s Chief Executive

MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc's Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO (Contract Development and Manufacturing Organization) in preparation for the upcoming production of the Company's lead asset, PRP, for the upcoming Phase 1b, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from solid tumors. In addition to touring the facility, t

Boca Raton, United States, June 11, 2026 (GLOBE NEWSWIRE) -- ShareStructure.io is proud to announce the launch of its free financial education and research platform focused on helping investors better understand public company capital structures, SEC filings, dilution risks, financing transactions, and shareholder-related developments. Through educational resources, research tools, and filing analysis, ShareStructure.io seeks to provide investors with greater transparency into public company financing activities and corporate actions. The platform was created to help retail investors better understand the public filings associated with stock tickers they follow and to make complex corpor